Archon Biosciences Analysis: $20M Raised
What is Archon Biosciences?
Computationally designed biologics for disease treatment
Location
Seattle, United States
Employees
11-50
Founded
2023
Product Features & Capabilities
- Antibody Cage (AbC) therapeutics
- Generative AI protein design platform
- Structural control for biodistribution and engagement
Use Cases
Targeting previously intractable drug discovery challenges; Designing AbCs for specific biological behaviors; Engineering AbCs for rapid preclinical development; Creating a scalable library of geometric and functional designs; Advancing drug characteristics like manufacturability and immunogenicity
Other Considerations
Co-founded by Nobel Prize winner David Baker; Emerged from stealth mode in 2024; Recognized for pioneering work in computational protein design
See something that needs updating? Suggest edits to this profile.